RAPT Therapeutics, Inc. announced the election of Peter Svennilson, Managing Partner of The Column Group, to its Board of Directors. Mr. Svennilson will replace David Goeddel, Ph.D., who did not stand for reelection to RAPT’s Board of Directors due to other responsibilities, but will remain a member of RAPT’s Scientific Advisory Board (SAB). Mr. Svennilson was elected to the Board of Directors at RAPT’s Annual Stockholder Meeting on June 18, 2020. He is currently Managing Partner and Founder of The Column Group. Prior to founding The Column Group, Mr. Svennilson founded Three Crowns Capital, where he served as Managing Partner, and before that was Associate Managing Director in charge of European Investment Banking Origination at Nomura Securities in London. In addition to serving on RAPT’s Board of Directors, Mr. Svennilson serves on the Boards of Directors of ORIC Pharmaceuticals, Inc., Ribon Therapeutics, Circle Pharma and Revolution Medicines, Inc. Previously, he served as Chairman of the Board of Directors of Seragon Pharmaceuticals, Inc. and Aragon Pharmaceuticals, Inc. Mr. Svennilson also served as a member of the Boards of Directors of Gritstone Oncology, Inc., Constellation Pharmaceuticals, Inc., NGM Biopharmaceuticals, Inc., PTC Therapeutics, Inc., Immune Design, Rosetta Inpharmatics LLC, ChemoCentryx, Inc. and Somalogic, Inc. and as Board Observer of Arcus Biosciences. Mr. Svennilson is currently a Trustee for The Institute for Advanced Study in Princeton, New Jersey.